The Kaplan–Meier curves for OS also showed similar results that patients with low levels of KLRB1 had longer survival times in BRCA (p < 0.001), CESC (p = 0.032), HNSC (p < 0.001), LUAD (p = 0.019), MESO (p = 0.003), pheochromocytoma and paraganglioma (PCPG) (p = 0.036), SARC (p = 0.001), SKCM (p < 0.001), THCA (p = 0.008), and UCEC (p = 0.012), while patients with low levels of KLRB1 experienced more favorable outcomes in LGG (p = 0.020) (Figure 2(c)). This evidence concerns the gene KLRB1 and paraganglioma.